1. Sweden Stocks

  2. •

    Health technology

  3. •

    Biotechnology
S2Medical AB Class B

S2Medical AB Class B

0.00
SEK
+0.00
(+11.11%)
8.84MMarket Cap
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
0.01
0.02
0.02
0.04
0.32
0.08
0.03
0.02
0.02
0.02
- -
Basic EPS, GAAP
-0.02
-0.12
-0.13
-0.23
-0.19
-0.2
-0.19
-0.06
0.01
-0.01
- -
Free Cash Flow per Basic Share
-0.06
-0.14
-0.19
-0.25
-0.19
-0.22
-0.19
-0.05
0.01
- -
- -
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
0.04
0.12
0.59
0.34
0.36
0.16
0.04
- -
0.02
0.01
0.02
Tangible Book Value per Share
0.01
0.08
0.53
0.25
0.27
0.03
-0.03
-0.02
0.01
- -
0.01
Basic Weighted Avg Shares
63
45
81
81
81
102
158
383
755
857
648
Sales/Revenue/Turnover
- -
1
1
3
26
8
5
7
15
14
- -
Operating Margin (%)
-307.94
-619.2
-709.19
-591.73
-58.8
-257.62
-592.88
-218.95
32.89
-18.55
- -
Depreciation Expense
- -
1
1
1
1
1
2
2
1
1
- -
Net Income, GAAP
-1
-5
-11
-18
-15
-20
-29
-23
5
-10
- -
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
-351.47
-637.35
-717.5
-595
-59.08
-260.78
-630.73
-325.73
32.78
-70.28
- -
Working Capital
2
5
38
17
23
1
-6
-11
-1
-3
-1
LT Debt
- -
3
2
1
- -
- -
- -
- -
- -
- -
- -
Total Equity
3
7
44
25
33
15
7
2
19
10
19
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
46.54
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
47.43
- -
- -
Return on Common Equity (%)
- -
-106.21
-42.15
-53.7
-52.11
-84.27
-270.86
-520.39
47.23
-70.61
- -

Capital Structure

SEK

•

in mil. unless spec.
Mar'24
Jun'24
Dec'24
ST Debt
- -
- -
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
476
498
1,135
Market Capitalization
21
13
9

Working Capital

SEK

•

in mil. unless spec.
Mar'24
Jun'24
Dec'24
Total Current Assets
9
5
6
Cash, Cash Equivalents & STI
1
1
1
Accounts Receivable, Net
1
1
2
Inventories
4
1
- -
Total Current Liabilities
19
7
7
Payables & Accruals
- -
- -
- -
ST Debt
- -
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

SEK

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
159.56%
-47.25%
Free Cash Flow
- -
-42.42%
-126.8%
Net Income, GAAP
- -
-74.9%
-309.79%
Sales/Revenue/Turnover
- -
9.67%
-2.15%
Total Cash Common Dividend
- -
- -
- -

Semi-annual Revenue

SEK

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
15
2025
7
- -
14
2026
7
- -
- -

Semi-annual Earnings Per Share

SEK

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
0.01
2025
- -
- -
-0.01
2026
- -
- -
- -

Semi-annual Dividends Per Share

SEK

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
- -
2025
- -
- -
- -
2026
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Petter Sivlér
Full Time Employees
10
Sector
Health technology
Industry
Biotechnology
Address
Sunnorpsgatan 5 Linköping OG Sweden 582 73
IPO Date
Nov 28, 2018
Website
s2m.se
Similar Companies
Moderna, Inc. (NASDAQ:MRNA)
Amgen Inc. (NASDAQ:AMGN)
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA)
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)
Novavax, Inc. (NASDAQ:NVAX)
10x Genomics, Inc. (NASDAQ:TXG)
Business
S2Medical AB (publ) (S2M.ST) develops, manufactures and commercializes innovative medical technologies focused on wound healing for burns and chronic wounds, infection control and cosmeceuticals; core products include Epiprotect, a biosynthetic cellulose wound dressing now owned by Epiprotect AB within the ABENA Group with S2Medical retaining production involvement; IvaQ, a CE-marked single-use negative pressure wound therapy system; Instagraft, a patented skin micro-transplantation device increasing donor-to-transplant ratios up to 1:100; ADMERCIN, an antimicrobial peptide platform targeting multi-drug resistant ESKAPE pathogens and enhancing antibiotic efficacy; Symbiovance, peptide-based functional skincare for licensing; and Eyracure (22.3% owned), a light-activated BIOlap20 peptide for hair repair commercialized via partners like LYKO; the company also operates S2Clinic wound healing centers. Founded in 2013 and headquartered in Linköping, Sweden, S2Medical lists on Nasdaq First North Growth Market Stockholm and serves healthcare providers, hospitals and dermatology markets across Europe, Middle East, Asia and beyond through exclusive distribution agreements in countries including Saudi Arabia, Philippines, Georgia, Turkey, UAE and Malaysia. Recent developments encompass successful completion of corporate reconstruction in April 2024 enabling debt-free status by May 2024; an agreement with ABENA in February 2024 for Epiprotect commercialization projecting tripled sales in 2024; offensive rights issue of SEK 11.5 million in August 2024; acquisition of additional shares in Eyracure AB in August 2024; US patent approval for Plantaricin NC8 antimicrobial technology in October 2024; exclusive distribution deals for Biopad in Philippines and cosmetic formulations with Eyracure in 2024; procurement wins in Sweden's Region Stockholm and South Africa patent for Eyracure's BioLAP-20; alongside IvaQ market readiness for 2025 partnerships.